Jordyn Sava is an assistant editor for Targeted Oncology.
Osimertinib Combo Significantly Reduces CNS Progression in EGFRm NSCLC
The FLAURA2 study found that osimertinib with platinum-pemetrexed was more effective than osimertinib monotherapy in preventing central nervous system progression or death in patients with EGFR-mutated advanced non–small cell lung cancer.
Real-World Data Confirms Efficacy of Tafasitamab for R/R DLBCL
In an interview with Targeted Oncology, Bruce Feinberg, DO, discussed the importance of real-world data, highlighting recent findings on tafasitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in the United States.
NCCN Updates Breast Cancer Guidelines to Include Goserelin
Goserelin is now included in the NCCN Breast Cancer Panel guidelines at 2 dosing schedules for ovarian function suppression in Version 1.2024.
Gallbladder Cancer: Progress and Hope for Future Breakthroughs
For Gallbladder Cancer Awareness Month, Horacio J. Asbun, MD, and Domenech Asbun, MD, shared their thoughts and strategies for treating patients with this disease from the surgical and clinical sides.
Dehumanizing Language is a Top Culprit in Prostate Cancer Research
In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the findings from her analysis of the Language of Respect guidelines adopted by the American Society of Clinical Oncology and how well they are followed in prostate cancer abstracts.
FRUTIGA Meets Primary End Point of PFS, Hints at OS Benefit in G/GEJ Cancer
Fruquintinib combined with paclitaxel significantly improved progression-free survival in patients with advanced gastric/GEJ cancer compared with paclitaxel alone.
In R/R Myeloma, Belantamab Mafodotin/BorDex Outperforms Standard Treatment
According to an interim analysis of the DREAMM-7 trial, belantamab mafodotin, bortezomib, and dexamethasone achieved a statistically significant and clinically meaningful improvement in progression-free survival among patients with multiple myeloma.
Stable Health, Function in BCG-Unresponsive NMIBC With N-803 Plus BCG
Available data on patient-reported outcomes and positive interim results from QUILT 3.032 support N-803 for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Beat AML Study Highlights Influential Factors in AML Treatment
In an interview with Targeted Oncology, Ashley Yocum, PhD, discussed The Beat AML study and emphasized the significance of considering patient factors, such as age and genetic mutations, in treatment decisions.
Vepdegestrant Gains FDA Fast Track Designation in ER+/HER2- Breast Cancer
If approved, vepdegestrant could provide a valuable new treatment option for patients with ER+/HER2- breast cancer who have progressed after receiving endocrine therapy.
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
FDA Clears IND for ACE2016 in EGFR-Expressing Solid Tumors
The allogeneic gamma delta 2 T-cell therapy ACE2016 will undergo investigation in a phase 1 trial for the treatment of patients with locally advanced or metastatic EGFR-expressing solid tumors.
Golidocitinib Induces Responses With Manageable Safety in R/R PTCL
In an interview with Targeted Oncology, Yuqin Song, MD, PhD, discussed golidocitinib as the first JAK1 inhibitor developed for patients with T-cell lymphomas in this pivotal study.
FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma
A fast track designation to UV1 combination therapy for malignant mesothelioma from the FDA signifies expedited review and development for a promising treatment option, offering hope for patients with malignant pleural mesothelioma.
World Cancer Day: Exploring Challenges and Advancements in Cancer Care
In an interview with Targeted Oncology, Michael Zinner, MD, explored the scientific challenges and breakthroughs shaping the landscape of oncology care in the context of World Cancer Day.
ECOG Score Predicts Survival Across Metastatic Prostate Cancer Settings
While ECOG performance status proves crucial for predicting survival in patients with metastatic prostate cancer, its specific impact on mCSPC needs further investigation.
FDA Grants Priority Review to BLA of Afami-cel in Synovial Sarcoma
Early data of afamitresgene autoleucel suggest substantial benefits for those with advanced synovial sarcoma who haven't responded to other treatments.
FDA Fast Tracks BST02 for Liver Cancer
The FDA granted a fast track designation to BST02 for patients with all forms of liver cancer.
Kasi Explores ctDNA and Other Advancements Reshaping GI Cancer Care
During a live event on Twitter/X, Pashtoon Kasi, MD, MS, discussed the potential of ctDNA and other advancements that have the potential to improve the lives of patients with GI cancers.
Beyond the First-Line: Economides on Advancing Therapies in RCC
In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
January 2024 FDA News Signals Progress in Cancer Treatment
Here is a look back at the FDA happenings from the month of January 2024.
Novel Agents and Potential Breakthroughs in HER2+ Breast Cancer Treatment
In the second article of a 2-part series, Yara Abdou, MD, provided a deep dive into the evolving landscape of HER2-targeted therapy and its potential to revolutionize cancer treatment.
Redefining Cancer Treatment With Personalized Medicine and Early Intervention
In an interview with Targeted Oncology, Geoffrey D. Moorer, MD, discussed recent trending topics in the field of oncology among hospital tumor boards and committees.
FDA Reopens Review of ProSense for Early-Stage Breast Cancer Treatment
The FDA has decided to re-evaluate the ProSense System as a minimally invasive treatment option for patients with early-stage, low-risk breast cancer.
Robotic Surgery Can Effectively Treat High-Risk EC After Prior Hysterectomy
Robotic peritoneal mesometrial resection with targeted or systemic lymphadenectomy demonstrated feasibility with acceptable complication rates in intermediate/high-risk endometrial cancer requiring second surgery after prior hysterectomy.
DSP-5336 is Well-Tolerated in R/R MLLr and NMP1-Mutant Acute Leukemia
In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the first-in-human, phase 1/2 study of DSP-5336 in patients with relapsed or refractory acute myeloid leukemia.
FDA Approves Manufacturing Change, Shortening Wait Time for Axi-cel
The axicabtagene ciloleucel manufacturing process has received FDA approval for a change to reduce the median turnaround time.
Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC
In an interview with Targeted Oncology, Thomas Powles, MD, MBBS, MRCP, discussed the impressive performance of enfortumab vedotin plus pembrolizumab for the treatment of locally advanced or metastatic urothelial carcinoma, as seen in the EV-302 trial.
FDA Clears IND for OriCAR-017 in Relapsed/Refractory Multiple Myeloma
The investigational new drug application for OriCAR-017 has been cleared by the FDA for the treatment of patients with relapsed/refractory multiple myeloma.
SYMPATICO Trial of Ibrutinib Plus Venetoclax Boosts PFS in MCL
Matthew Matasar, MD, discussed the rationale and findings of the doublet consisting of ibrutinib and venetoclax for the treatment of mantle cell lymphoma.
2 Commerce Drive Cranbury, NJ 08512